Expertise in
11
conditions

Dr. James Hoffman

Oncology
Baystate Specialty Pharmacy
3300 Main St, 
Springfield, MA 
Expertise in
11
conditions
Baystate Specialty Pharmacy
3300 Main St, 
Springfield, MA 

Overview

James Hoffman is an Oncologist practicing medicine in Springfield, Massachusetts.

Dr. Hoffman is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Malignant Mixed Mullerian Tumor, Ovarian Cancer, Endometrial Cancer, and Sertoli-Leydig Cell Tumor.

He is actively involved in clinical research, co-authoring 7 peer reviewed articles and participating in 7 clinical trials.

Specialties

Oncology

Licenses

Obstetrics & Gynecology in MA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Baystate Specialty Pharmacy
3300 Main St, Springfield, MA 01107

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer
A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer
Enrollment Status: Completed
Publish Date: November 13, 2025
Intervention Type: Other, Drug
Study Drugs: Letrozole, Paclitaxel, Pegylated liposomal doxorubicin hydrochloride, Tamoxifen citrate, Topotecan, Trametinib dimethyl sulfoxide
Study Phase: Phase 2/Phase 3
Comparative Analysis of CA-IX, p16, Proliferative Markers, and Human Papilloma Virus (HPV) in the Diagnosis of Significant Cervical Lesions in Patients With a Cytologic Diagnosis of Atypical Glandular Cells (AGC)
Comparative Analysis of CA-IX, p16, Proliferative Markers, and Human Papilloma Virus (HPV) in the Diagnosis of Significant Cervical Lesions in Patients With a Cytologic Diagnosis of Atypical Glandular Cells (AGC)
Enrollment Status: Active_not_recruiting
Publish Date: May 03, 2024
Intervention Type: Other
Study Phase: Not Applicable
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
Enrollment Status: Completed
Publish Date: November 07, 2022
Intervention Type: Other, Drug, Radiation
Study Drugs: Carboplatin, Cisplatin, Paclitaxel
Study Phase: Phase 3
A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia
A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia
Enrollment Status: Completed
Publish Date: August 12, 2022
Intervention Type: Other, Drug, Biological
Study Drugs: Dactinomycin, Leucovorin Calcium, Methotrexate
Study Phase: Phase 3
A Phase II Evaluation of Copanlisib (BAY 80-6946), a Selective Inhibitor of PI3KCA, in Patients With Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations
A Phase II Evaluation of Copanlisib (BAY 80-6946), a Selective Inhibitor of PI3KCA, in Patients With Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations
Enrollment Status: Completed
Publish Date: February 15, 2022
Intervention Type: Drug, Other
Study Drug: Copanlisib
Study Phase: Phase 2
A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary
A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary
Enrollment Status: Unknown
Publish Date: January 25, 2022
Intervention Type: Biological, Drug, Other
Study Drugs: Bleomycin Sulfate, Carboplatin, Cisplatin, Etoposide Phosphate, Paclitaxel
Study Phase: Phase 2
Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?
Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?
Enrollment Status: Unknown
Publish Date: February 19, 2018
Intervention Type: Other, Behavioral
Study Phase: Phase 3
View 6 Less Clinical Trials

7 Total Publications

A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D.
A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D.
Journal: Gynecologic oncology
Published: August 17, 2016
Similar Doctors
Expertise in
48
conditions
Dr. John Mccann
Oncology
Expertise in
48
conditions
Dr. John Mccann
Oncology

Baystate Hematology Oncology

3350 Main St, 
Springfield, MA 
 (0.1 miles away)
413-794-9338
Languages Spoken:
English
See accepted insurances
Offers Telehealth

John Mccann is an Oncologist practicing medicine in Springfield, Massachusetts. Dr. Mccann is highly rated in 48 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Pleuropulmonary Blastoma, Non-Small Cell Lung Cancer (NSCLC), and Small Cell Lung Cancer (SCLC).

Expertise in
16
conditions
Dr. Scott Gettinger
Oncology
Expertise in
16
conditions
Dr. Scott Gettinger
Oncology

Yale New Haven Hospital

20 York St, 
New Haven, CT 
 (59.0 miles away)
203-200-5864
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Scott Gettinger is an Oncologist practicing medicine in New Haven, Connecticut. Dr. Gettinger is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), EGFR Positive Lung Cancer, and Gamma Knife Radiosurgery.

Expertise in
33
conditions
Dr. Elena Ratner
Oncology
Expertise in
33
conditions
Dr. Elena Ratner
Oncology

Yale New Haven Hospital

20 York St, 
New Haven, CT 
 (59.0 miles away)
203-785-7385
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Elena Ratner is an Oncologist practicing medicine in New Haven, Connecticut. Dr. Ratner is highly rated in 33 conditions, according to our data. Her clinical expertise encompasses Ovarian Carcinosarcoma, Ovarian Cancer, Endometrial Cancer, Oophorectomy, and Hysterectomy.

Frequently Asked Questions about Dr. James Hoffman

How do I make an appointment with Dr. James Hoffman?

You can book an appointment with Dr. James Hoffman by calling their office at 413-794-9338. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. James Hoffman a top-rated expert for Malignant Mixed Mullerian Tumor?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. James Hoffman is classified as an Advanced expert for Malignant Mixed Mullerian Tumor, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. James Hoffman specialize in?

While Dr. James Hoffman is a Oncology, they have specific expertise in Malignant Mixed Mullerian Tumor, Ovarian Cancer, and Endometrial Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. James Hoffman participate in research or clinical trials?

Yes. Dr. James Hoffman has published 7 articles and abstracts on conditions like Malignant Mixed Mullerian Tumor. You can view a list of Dr. James Hoffman's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hoffman's expertise for a condition
ConditionClose
      View All 11 Advanced Conditions
      View All 14 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile